Table 3 Summary of findings of shoulder arthroplasty
Outcomes | N | Patients (TXA/non-TXA) | Overall effect | Heterogeneity | ||
|---|---|---|---|---|---|---|
RR or MD (95% CI) | P | I2 | P | |||
Rate of blood transfusion | ||||||
 All included studies | 5 | 319/313 | 0.34 [0.14, 0.79] | 0.02 | 0% | 0.42 |
 Randomized controlled trials | 3 | 136/131 | 0.23 [0.07, 0.77] | 0.01 | NA | NA |
 RTSA | 4 | 141/150 | 0.28 [0.10, 0.83] | 0.02 | 0% | 0.47 |
Estimated total blood loss (ml) | ||||||
 All included studies | 3 | 157/170 | -249.24 [−338.74, −159.74] | <  0.00001 | 20% | 0.29 |
 Randomized controlled trials | 2 | 80/76 | − 357.92 [− 504.25, −211.59] | <  0.00001 | 0% | 0.87 |
 RTSA | 2 | 95/101 | −249.15 [−426.60, −71.70] | 0.006 | 64% | 0.10 |
Hb change within 48Â h after surgery (g/dl)a | ||||||
 All included studies | 5 | 316/310 | −0.64 [− 0.81, − 0.46] | 0.009 | 0% | 0.72 |
 Randomized controlled trials | 2 | 109/104 | −0.65 [− 1.14, − 0.16] | <  0.00001 | 42% | 0.19 |
 RTSA | 4 | 153/158 | −0.64 [− 0.86, − 0.42] | <  0.0001 | 0% | 0.66 |
 IV TXA | 5 | 260/255 | −0.60 [− 0.79, − 0.41] | <  0.0001 | 0% | 0.79 |
 Topical TXA | 1 | 56/55 | −0.90 [− 1.42, − 0.38] | 0.0007 | NA | NA |
Blood loss via drainage within 48Â h after surgery (ml)a | ||||||
 All included studies | 4 | 160/155 | −95.41 [−139.86, − 50.96] | <  0.001 | 65% | 0.04 |
 Randomized controlled trials | 3 | 136/131 | −105.78 [− 159.88, −51.68] | 0.001 | 71% | 0.03 |
 RTSA | 3 | 111/106 | −84.56 [−145.72, −23.39] | 0.007 | 80% | 0.007 |
 IV TXA | 3 | 104/100 | −110.04 [− 159.03, −61.06] | <  0.0001 | 65% | 0.04 |
 Topical TXA | 1 | 56/55 | −60.00 [−103.29, − 16.71] | 0.007 | NA | NA |
Operation time (min) | 3 | 183/161 | −1.08 [−4.91, 2.74] | 0.58 | 0% | 0.42 |
Hospital stay (day) | 2 | 159/137 | − 0.04 [− 0.45, 0.37] | 0.84 | 75% | 0.05 |
Overall complications | 6 | 343/337 | 0.44 [0.07, 2.96] | 0.40 | 0% | 0.95 |
Thromboembolic events | 6 | 343/337 | 0.31 [0.01, 7.40] | 0.47 | NA | NA |